[关键词]
[摘要]
病理性近视(PM)以眼轴进行性延长、后巩膜葡萄肿及眼底退行性病变为特征,是亚洲国家主要致盲眼病之一。后巩膜加固术(PSR)是目前唯一手术干预延缓眼轴增长的手段,机制涉及机械加固、改善血循环及生物刺激巩膜重塑。文章综述PSR最新进展:手术方式从经典复杂术式向标准化单条带技术演变,联合三维MRI量化后巩膜葡萄肿形态以指导个体化植片设计,推动微创精准化; 植入材料中,异体硬脑膜等生物材料持续优化,仿生压电智能材料通过电信号主动促进巩膜胶原合成,实现从“被动支撑”到“主动强化”的跨越; 临床疗效上,控制眼轴、改善视功能及血循环、儿童早期干预获益; 联合ICL、白内障或玻璃体切除术为不同患者提供综合方案。文章还分析了后巩膜葡萄肿异位、二次手术等长期问题及核心争议,并对人工智能辅助、智能材料转化及全周期防治体系等未来方向进行展望,以期为临床与科研提供参考。
[Key word]
[Abstract]
Pathologic myopia(PM)is characterized by progressive axial elongation, posterior staphyloma, and fundus degenerative changes, representing a leading cause of blindness in Asian countries.Posterior scleral reinforcement(PSR)is currently the only surgical intervention to slow axial elongation. Its mechanisms involve mechanical reinforcement, improved blood circulation, and biological stimulation of scleral remodeling. This article reviews recent advances in PSR: surgical techniques have evolved from complex, classic procedures to standardized single-strip methods, incorporating 3D MRI to quantify posterior staphyloma morphology for personalized graft design and facilitating minimally invasive, precision surgery. Among implant materials, biomaterials such as allogeneic dura mater are being continuously optimized, while biomimetic piezoelectric smart materials actively promote scleral collagen synthesis through electrical signals, achieving a paradigm shift from “passive support”to “active reinforcement”. Clinical outcomes indicate advantages in regulating axial length, enhancing visual function and blood circulation, and facilitating early intervention in children. Combined procedures with ICL implantation, cataract surgery or vitrectomy provide comprehensive treatment regimens for individual patients with varied conditions. This article also analyzes long-term issues and core controversies including ectopic posterior staphyloma and reoperation, and prospects future research directions such as artificial intelligence assistance, translation of smart materials and full-cycle prevention and treatment systems, so as to provide references for clinical practice and scientific research.
[中图分类号]
[基金项目]
深圳市基础研究专项(自然科学基金)项目(No.JCYJ20240813165100001); 深圳眼科医院科研基金项目(No.SZAE2023B03); 爱尔眼科医院集团科研基金(No.AGF2301D34)